Brian Walter Eastman

This inventor holds 34 USPTO granted patents and 8 published patent applications and 7 EPO patents, primarily in Pharmaceutical Chemistry. Top assignees: Samumed, LLC, Merck Sharp + Dohme Corp., Biosplice Therapeutics, Inc.. Active years: 2003-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Brian Walter Eastman. Retrieved from https://idiyas.com/inventor/brian-walter-eastman

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 34 (Patent Applications = 8)

% Patents Active = 70.6

EPO Patents = 7 (Patent Applications = 10)

Average Co-Inventor Count = 7.5

ph-index = 6

Forward Citations = 316(Granted Patents)

Company Filing History:

Merck Sharp + Dohme Corp.

patents

4 out of 19

Biosplice Therapeutics, Inc.

patents

4. 4 out of 17

Sgx Pharmaceuticals, Inc.

patents

5. 3 out of 174

Agouron Pharmaceuticals, Inc.

Rempex Pharmaceuticals, Inc.

Years Active: 2003-2026

Loading Chart...

Areas of Expertise:

Carboxamides

Kinase Modulators

Efflux Pump Inhibitors

Thiazolyl Antagonists

Fused Ring Heterocycles

Indazole Compounds

Isoquinolin Derivatives

Antiviral Compounds

Poly(ADP-Ribose) Polymerases

Pyrrolo Compounds

Bacterial Inhibitors

Pharmaceutical Uses

34 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12729205 - 4-alkoxypyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof (2026-09-08),

2. 12281097 - Isoquinolin-3-yl carboxamides and preparation and use thereof (2025-04-21),

3. 12134625 - Pyrrolo[2,1-f][1,2,4]triazines and preparation and uses thereof (2024-11-05),

4. 11713320 - 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof (2023-08-01),

5. 11548872 - Isoquinolin-3-yl carboxamides and preparation and use thereof (2023-01-10),

6. 10947217 - Isoquinolin-3-YL carboxamides and preparation and use thereof (2021-03-16),

7. 10934297 - 5-heteroaryl substituted indazole-3-carboxamides and preparation and use thereof (2021-03-02),

8. 10744128 - 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof (2020-08-18),

9. 10703748 - Diazanaphthalen-3-yl carboxamides and preparation and use thereof (2020-07-07),

10. 10669240 - 5-substituted indazole-3-carboxamides and preparation and use thereof (2020-06-02),

11. 10653688 - 6-(6-membered heteroaryl and aryl)isoquinolin-3-yl carboxamides and preparation and use thereof (2020-05-19),

12. 10604514 - 6-(5-membered heteroaryl)isoquinolin-3-yl carboxamides and preparation and use thereof (2020-03-31),

13. 10544128 - Isoquinolin-3-yl carboxamides and preparation and use thereof (2020-01-28),

14. 10413537 - 6-(5-membered heteroaryl)isoquinolin-3-yl-(5-membered heteroaryl) carboxamides and preparation and use thereof (2019-09-17),

15. 10106527 - Isoquinolin-3-yl carboxamides and preparation and use thereof (2018-10-23),

Title: Brian Walter Eastman: Innovator and Patent Holder in Medical Compounds

Introduction

Brian Walter Eastman, based in San Diego, California, is a prolific inventor with a remarkable portfolio that includes 32 patents. His work primarily focuses on the development of innovative compounds aimed at treating various diseases and health-related issues.

Latest Patents

Two of his latest patents include groundbreaking formulations that promise to advance medical treatment. The first patent relates to Pyrrolo[2,1-f][1,2,4]triazine compounds, which are designed for treating diseases characterized by the overexpression of DYRK1A, such as cancer, Alzheimer's disease, Down syndrome, diabetes, viral infections, and osteoarthritis. The second patent encompasses 5-heteroaryl substituted indazole-3-carboxamides, targeting disorders related to the activation of Wnt pathway signaling, including various dermatological conditions, cancer, and neurological disorders that also link back to DYRK1A overexpression.

Career Highlights

Brian has contributed significantly to the fields of medicinal chemistry and pharmacology through his affiliations with reputable companies such as Samumed, LLC and Merck Sharp & Dohme Corporation. His career in these organizations has been marked by a commitment to innovation and a passion for developing treatments that address pressing health challenges.

Collaborations

Throughout his career, Brian has worked alongside esteemed colleagues, including Chi Ching Mak and Gopi Kumar Mittapalli. These collaborations have not only enriched his professional journey but have also played an essential role in advancing the research and development of his innovative compounds.

Conclusion

In summary, Brian Walter Eastman stands out as an influential figure in the realm of medical innovation. His extensive patent portfolio and contributions through collaboration underscore his ongoing commitment to improving human health and addressing complex medical issues. His work continues to hold promise for advancing therapeutic options and enhancing patient outcomes.

Profile summary based on public USPTO records.